Checkpoint inhibitor boosts survival in relapsed malignant mesothelioma: study
Preliminary results are the first to show benefit for this population in a phase 3 trial, researcher says
Treatment with the programmed death-1 (PD-1) inhibitor nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma, a study shows.
The CONFIRM phase 3 trial enrolled 332 adults with previously treated, unresectable malignant mesothelioma and Eastern Co-operative Oncology Group performance status of zero to one.
Patients were stratified by epithelioid and non-epithelioid history and randomly allocated to nivolumab (240mg on a 14-day cycle, 221 patients) or placebo (111
